Depigmentation for vitiligo: the permanent option
Depigmentation is clinician-led care with a prescribed medicine, not something you can buy or do to yourself.
What you are deciding
The permanent direction · taking the pigment you still have away, not bringing color back
- What it aims to do
- Take away the pigment you still have so your skin looks more even, rather than bring color back to a pale patch. The US label for Benoquin (monobenzone), the medicine used for this, says it can destroy pigment cells.
- What permanent means here
- That same label warns the change can be permanent and irreversible. It cannot be treated as a trial run. There is no version of this you begin and then stop if the result comes out uneven, or is not what you pictured.
- What the label does not settle
- Whether depigmentation fits you. It does not stand in for what your own clinician tells you. It says nothing about the identity and mental-health side of permanently changing how you look.
Ask for psychological and identity support before any medicine or procedure detail. A permanent choice deserves time, privacy and freedom from pressure. There is no right answer for everyone: choosing it, declining it, and never deciding are all real outcomes.
Last updated
Most vitiligo pages discuss bringing pigment back. This page discusses the opposite direction. SteadySkin is not for or against it.
Before medicine or procedure details, ask for psychological support and an identity conversation. A permanent choice deserves time, privacy, and freedom from pressure.
What depigmentation means
The aim is to remove remaining pigment so skin looks more even, not to repigment a patch.
The FDA label for Benoquin (monobenzone) warns that it can destroy pigment cells and cause permanent, irreversible depigmentation. This is clinician-led care, not a cosmetic product or a do-it-yourself path.
Ask your care team Keep safety, treatment, and irreversible choices with the team that knows your health, skin, and goals.
The permanent part - read it again
Permanent means the decision cannot be treated as a trial run.
Depigmentation can be irreversible. Ask what cannot be undone, what may be uncertain, and what long-term care would become part of your life.
Do not begin because another person wants an even tone, because a deadline is close, or because you feel pushed to choose a side.
Ask your care team Keep safety, treatment, and irreversible choices with the team that knows your health, skin, and goals.
Put psychological and identity support first
A mental-health conversation is not a judgment about wanting depigmentation.
- Talk through what changing your remaining color means to you.
- Name any racial, cultural, religious, family, or safety concerns.
- Ask how you might feel during change, after change, and if the result is uneven.
- Choose who, if anyone, you want involved in the decision.
- Give yourself permission to stop the process before it starts.
Ask your care team Keep safety, treatment, and irreversible choices with the team that knows your health, skin, and goals.
Sun protection becomes lifelong
The label says the skin stays sensitive to sun for the rest of your life.
The FDA-hosted Benoquin label puts this under Precautions. It states that following therapy the skin will be sensitive for the rest of the patient’s life. It states that the person must use sunscreens during exposure to the sun. Those are the label’s words. What they mean for your skin, your climate and your working day is a question for your prescriber, and this page sets no rule for you.
The same label describes what is left behind. It says the skin after depigmentation with topical monobenzone looks under a microscope like vitiligo skin: the epidermis is normal, except that no pigment cells can be identified. The American Academy of Dermatology says skin that has lost its color can burn readily, and names shade, clothing and labeled sunscreen as broad options. Today that applies to your patches. After depigmentation it applies to all of your skin.
The label does not say what a lifetime of that adds up to. Under Carcinogenesis it states that no long term studies have been performed to evaluate carcinogenic potential. The document carries a printed revision of August 2000 and an FDA banner saying it may not be the latest approved label. So the long-term question is open in the document itself, and nothing here fills it in from elsewhere.
SteadySkin is not for or against depigmenting. This is here so the routine is something you can weigh before you decide, rather than meet afterwards.
Ask your care team Keep safety, treatment, and irreversible choices with the team that knows your health, skin, and goals.
Sun during the course, not only after
The label says sunlight works against the medicine while you are using it.
Two parts of the label say so. Under Clinical Pharmacology it states that exposure to sunlight reduces the depigmenting effect of the drug. Under Dosage and Administration it states that prolonged exposure to sunlight should be avoided during treatment, or that a sunscreen should be used.
That is the reverse of phototherapy, where the light is the treatment. It is worth knowing before you start rather than partway through. Neither the label nor this page sets a limit for you.
Lived experience - useful, real, and different for everyone
No countdown and no nudge
Choosing depigmentation, declining it, or never deciding are all legitimate outcomes.
Some people may feel relief. Others may feel grief. You may feel both, neither, or change your mind before treatment. A permanent and irreversible option should never be sold as the brave choice or the final step you owe yourself.
Ask your care team Keep safety, treatment, and irreversible choices with the team that knows your health, skin, and goals.
What should I ask at my next appointment?
Use these words as written, or change them to fit what you need.
- Before we discuss treatment, can we arrange psychological and identity support?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Please explain every permanent and irreversible part in plain language.Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What remains uncertain, and what long-term care would this choice require?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- If I decide no, pause, or never choose this, what support remains available?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- The label says the skin stays sensitive to sun for life. What would that look like on an ordinary day for me?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- How would sun protection change for the parts of my skin that still have color?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The product company authored the prescribing information hosted by FDA. It is authoritative for the historical label but not independent clinical evidence.
What this source supports
Supports the historical US indication for final depigmentation in extensive disseminated idiopathic vitiligo, the purpose and mechanism limits, permanence and distant-depigmentation warnings, listed reactions, contraindication boundary, and long-term unknowns. Re-read in full on 2026-08-21 for what it states about sun, which is in three places. Under Precautions, General, it states that following therapy with the cream the skin will be sensitive for the rest of the patient’s life, and that the person must use sunscreens during exposure to the sun. Under Clinical Pharmacology it states that exposure to sunlight reduces the depigmenting effect of the drug. The same section states that the histology of the skin after depigmentation with topical monobenzone is the same as that seen in vitiligo, the epidermis being normal except for the absence of identifiable melanocytes. Under Dosage and Administration it states that prolonged exposure to sunlight should be avoided during treatment, or that a sunscreen should be used. Under Carcinogenesis, mutagenesis, impairment of fertility it states that no long term studies have been performed to evaluate carcinogenic potential.
What it does not support
The archived label does not establish current commercial availability, approval of a compounded preparation, predictable uniform results, suitability, a personal plan, or current status outside the US. Its sun statements are the label instructing a patient under a prescriber; SteadySkin reports them as the label’s wording and issues none of them as advice. It sets no sun protection factor, no interval and no exposure limit, and it measures nothing about how depigmented skin behaves in sunlight beyond the sensitivity statement itself. Because it performed no long term carcinogenicity study, it establishes nothing about skin cancer risk after depigmentation in either direction. The document carries a printed revision of August 2000 and an FDA banner stating it may not be the latest approved label, so it is used only for what it plainly states and never as current guidance.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports patient-facing context that skin which has lost its color can burn readily and that shade, clothing and labeled sunscreen use are broad protection options. It also supports that for some people a skin injury triggers new spots or patches, and it names cuts, scrapes and burns. The wound a tattoo makes can lead to the Koebner phenomenon, with new spots appearing about 10 to 14 days later. It supports that a tattoo added for pigment may not blend with natural skin color, that its color can eventually bleed, and that the vitiligo underneath can spread over time. It supports the page telling readers to avoid tanning, indoors and outdoors, because tanning increases the contrast between natural skin color and the light spots and patches. That is what it says makes vitiligo more noticeable. It supports that tanning beds, sun lamps and other indoor tanning devices are not safe alternatives to the sun. Like the sun, they can burn skin that has lost pigment and worsen vitiligo. It supports that a bad sunburn can worsen vitiligo, and that on a lighter skin tone untanned skin often makes the spots and patches less noticeable. It supports that self-tanners and skin dyes tend to last 3 to 5 days, against one day for makeup. It names dihydroxyacetone as the ingredient to look for, and says natural-looking results take practice. It supports that vitiligo increases the risk of some other diseases such as thyroid disease, and that a dermatologist can monitor for them.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish treatment efficacy. It does not establish a personalized sun plan, a product ranking or a treatment-day instruction. It gives no frequency for injury-related patches and no way to tell in advance who they happen to. It gives no measure of how much tanning changes contrast, no threshold for a bad sunburn, and no way to tell whether one person’s vitiligo will worsen. It compares no tanning device with prescribed narrowband UVB and establishes nothing about medical phototherapy. It names no product or brand for camouflage, self-tanner or skin dye.